ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4215-Southport-Gold-Coast-University-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
28
trial(s) found.
NCT06726265
Advanced
Phase 3
Recruiting
TACTI-004
, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.
T-cell immunostimulatory factor
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Gold Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT06692738
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02) (
D702BC00001
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT06627647
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03) (
D702FC00001
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-squamous non-small-cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT06357533
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (
TROPION-Lung10
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4215 - Southport - Gold Coast University Hospital (WITHDRAWN)
NCT06356129
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (
GOLSEEK-1
)
CELMoD agent
placebo
Diffuse large B-cell lymphoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06351631
Haem
Phase 3
Recruiting
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study (
3543-017
)
LSD1 inhibitor
Myelofibrosis
Polycythemia vera
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06305962
Radonc
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours (
177Lu-RAD204.2023.0001
)
radioconjugate,PD-L1-targeting
Cutaneous melanoma
Endometrial cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4215 - Southport - Gold Coast University Hospital
4509 - North Lakes - Icon Cancer Centre North Lakes
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06225596
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (
BT8009-230
)
bicycle toxin conjugate,NECTIN4-targeting
Urothelial carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06208150
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide (
MonumenTAL-6
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Perth Blood Institute
NCT06188208
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors (
VVD-130850-01
)
STAT3 inhibitor
Haematological malignancy
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06119581
Advanced
Phase 3
Recruiting
SUNRAY-01
, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
antimetabolite
placebo
Non-small cell lung cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06018337
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (
DB-1303-O-3002
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05514054
Curative
Phase 3
Recruiting
EMBER-4
: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
selective estrogen receptor degrader
Breast cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4215 - Southport - Gold Coast University Hospital
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT05445778
Curative
Phase 3
Recruiting
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (
GLORIOSA
)
anti-FR-alpha antibody-drug conjugate
anti-VEGF monoclonal antibody
Fallopian tube cancer
Ovarian cancer
Peritoneal cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4215 - Southport - Gold Coast University Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05352672
Paed
Phase 3
Recruiting
A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (
R3767-ONC-2011
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
4215 - Southport - Gold Coast University Hospital (SUSPENDED)
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT05261399
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (
SAFFRON
).
EGFR inhibitor,third generation
MET inhibitor,type 1
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (WITHDRAWN)
QLD
4215 - Southport - Gold Coast University Hospital
WA
6150 - Murdoch - St John of God Murdoch Hospital
NCT05222087
Radonc
Phase 1
Recruiting
PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer. A Pilot Study (
PRIME-LUNG
)
radiotherapy
Non-small cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
NCT04996875
Haem
Phase 2
Recruiting
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis (
CGT9486-20-201
)
KIT D816V inhibitor
KIT inhibitor,type 1
Haematological malignancy
Mast cell leukaemia
Systemic mastocytosis
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
NCT04811560
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (
CR108998
)
KMT2A inhibitor
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Leukaemia
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04771130
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
BGB-11417-103
)
Bcl2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12624000141549
Haem
Phase 1 / Phase 2
Not yet recruiting
AMLM26/T2- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - Ivosidenib + Venetoclax (
AMLM26-T2
)
Bcl2 inhibitor
IDH1 R132 inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12624000082505
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T1- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre- emptive Therapy in AML): A Multi-arm, Precision- based, Recursive, Platform Trial - Gilteritinib+ Venetoclax (
AMLM26-T1--INTERCEPT
)
AXL/FLT3 inhibitor
Bcl2 inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12622001200774
Radonc
Phase 3
Recruiting
Conventional or Stereotactic Radiotherapy for the palliation of non-spine bone metastases: A randomised phase III trial. (
CONSOLE
)
radiotherapy
Cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3121 - Richmond - Epworth Freemasons Hospital
3170 - Mulgrave - Icon Cancer Centre Mulgrave
QLD
4215 - Southport - Gold Coast University Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622000856718
Haem
Phase 1 / Phase 2
Not yet recruiting
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study assessing safety and tolerability of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (
ISB-1442-101
)
bispecific CD38/CD47 antibody
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622000582752
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T4- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - SNDX5613 (
AMLM26-T4
)
Revumenib
cancer therapy
cancer therapy,KMT2A-targeting
cancer therapy,menin-targeting
menin-MLL1 inhibitor
menin inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621001529831
Haem
Phase 2
Recruiting
NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL). (
PACIFIC
)
anti-PD-1 monoclonal antibody
B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12621001444875
Radonc
Phase 2
Recruiting
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study) (
The-SOCRATES-HCC-Study
)
Radiotherapy
cancer therapy
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT05450744
Advanced
Phase 1
Unknown
A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma (
IPAX-2
)
131I-IPA
131I-TLX-101
cancer therapy
cancer therapy,LAT1-targeting
cancer therapy,LAT2-targeting
radioiodine conjugate
radioiodine therapy
radioligand,LAT1/LAT2-targeting
radiopharmaceutics
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (25)
Not yet recruiting (2)
Unknown (1)
Recruitment Country and State
QLD (28)
NSW (24)
VIC (23)
SA (16)
WA (15)
NZ (5)
TAS (4)
NT (2)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (6)
Phase 2 (3)
Phase 2 / Phase 3 (1)
Phase 3 (14)
Trial Type
Advanced (10)
Haem (10)
Radonc (4)
Curative (2)
Paed (2)
Cancer Therapy Class
PD-1/PD-L1
36%
PD-1
32%
TIGIT
11%
Bcl2
11%
CD20
7%
cereblon
7%
PD-L1
7%
KMT2A
7%
Trop2
4%
LSD1
4%
Nectin-4
4%
BCMA
4%
CS1
4%
GPRC5D
4%
proteasome
4%
STAT3
4%
KRAS
4%
KRAS G12C
4%
ERBB2
4%
ER
4%
oestrogen axis
4%
FR-alpha
4%
VEGF
4%
LAG3
4%
EGFR
4%
MET
4%
KIT
4%
DNA methyltransferase
4%
IDH1
4%
IDH1 R132
4%
AXL
4%
FLT3
4%
CD38
4%
CD47
4%
menin
4%
LAT1
4%
LAT2
4%
Facility
4215 - Southport - Gold Coast University Hospital (28)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (13)
3168 - Clayton - Monash Medical Centre (10)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (9)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (8)
2050 - Camperdown - Chris O'Brien Lifehouse (8)
3000 - Melbourne - Peter MacCallum Cancer Centre (7)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (7)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (6)
4102 - Woolloongabba - Princess Alexandra Hospital (6)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (5)
3004 - Melbourne, Southbank - Alfred Health (5)
6150 - Murdoch - Fiona Stanley Hospital (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
2500 - Wollongong - Wollongong Hospital (4)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
4575 - Birtinya - Sunshine Coast University Hospital (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
2170 - Liverpool - Liverpool Hospital (4)
2139 - Concord - Concord Repatriation General Hospital (4)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
3021 - St Albans - Western Health - Sunshine Hospital (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (3)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (3)
7000 - Hobart - Royal Hobart Hospital (3)
4812 - Hyde Park - Icon Cancer Centre Townsville (2)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (2)
NZ.0622 - Takapuna - North Shore Hospital (2)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
3630 - Shepparton - Goulburn Valley Health (2)
4740 - Mackay - Mackay Base Hospital (2)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (2)
3066 - Epping - Northern Hospital (2)
3121 - Richmond - Epworth Freemasons Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2500 - Wollongong - Cancer Care Wollongong (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
4509 - North Lakes - Icon Cancer Centre North Lakes (1)
6150 - Murdoch - GenesisCare Murdoch (1)
2031 - Randwick - Prince of Wales Hospital (1)
6005 - West Perth - Perth Blood Institute (1)
2109 - North Ryde - Macquarie University Hospital (1)
2060 - North Sydney - Mater Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
3135 - Ringwood East - Maroondah Hospital (1)
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
6150 - Murdoch - St John of God Murdoch Hospital (1)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (1)
6000 - Perth - Royal Perth Hospital (1)
2217 - Kogarah - St George Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
6009 - Nedlands - One Clinical Research (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
3170 - Mulgrave - Icon Cancer Centre Mulgrave (1)
4217 - Benowa - Pindara Private Hospital (1)
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Acute myeloid leukaemia
Leukaemia
Myeloid leukaemia
Breast cancer
B-cell lymphoma
B-cell malignancy
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Myeloproliferative neoplasm
Gynaecological cancer
Melanoma
Multiple myeloma
Plasma cell disorder
Non-squamous non-small-cell lung cancer
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Myelofibrosis
Polycythemia vera
Breast adenocarcinoma
Carcinoma
Cutaneous melanoma
Endometrial cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Neuroendocrine carcinoma
Skin cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Triple-negative breast cancer
Urogenital cancer
Urothelial carcinoma
Fallopian tube cancer
Ovarian cancer
Peritoneal cancer
Mast cell disorder
Mast cell leukaemia
Systemic mastocytosis
Acute lymphoblastic leukaemia
Lymphoid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Gastrointestinal cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Upper gastrointestinal cancer
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy